AMGN.MX
Amgen Inc. News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 6,
"returned": 5,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "3c6737e4-a88f-45ac-a16e-e43fdb6a3ac7",
"title": "Amgen : Expanding Innovation in BiTE® Technology for Patients with Extensive Stage Small Cell Lung Cancer (ES SCLC)",
"description": "Amidst the lung cancer landscape, small cell lung cancer comprises about 15% of the 2.4 million plus patients diagnosed with lung cancer worldwide each year.1-3 SCLC progresses rapidly, with...",
"keywords": "Markets",
"snippet": "This is an abstract of the document. To keep reading, click here and get access to the original version.\n\nAttachments Original Link\n\nPermalink\n\nDisclaimer Amgen...",
"url": "https://www.marketscreener.com/quote/stock/AMGEN-INC-4847/news/Amgen-Expanding-Innovation-in-BiTE-Technology-for-Patients-with-Extensive-Stage-Small-Cell-Lung-46753095/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
"language": "en",
"published_at": "2024-05-16T23:34:06.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "AMGN.MX",
"name": "Amgen Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 43.072495,
"sentiment_score": 0.13465,
"highlights": [
{
"highlight": "Attachments Original Link\n\nPermalink\n\nDisclaimer <em>Amgen</em> <em>Inc</em>. published this content on 16 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 May 2024 23:33:01 UTC.",
"sentiment": 0.6908,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Amgen</em> : Expanding Innovation in BiTE® Technology for Patients with Extensive Stage Small Cell Lung Cancer (ES SCLC)",
"sentiment": -0.4215,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "079b913c-3417-498b-bc46-9efac65b4129",
"title": "US FDA approves Amgen drug for small cell lung cancer, Bloomberg News reports",
"description": "The U.S. Food and Drug Administration\ngranted accelerated approval to tarlatamab, Amgen's\ntargeted immunotherapy for treating adults with advanced small\ncell lung cancer that has worsened despite...",
"keywords": "Markets",
"snippet": "Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating ca...",
"url": "https://www.marketscreener.com/quote/stock/AMGEN-INC-4847/news/US-FDA-approves-Amgen-drug-for-small-cell-lung-cancer-Bloomberg-News-reports-46751575/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
"language": "en",
"published_at": "2024-05-16T19:13:55.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "AMGN",
"name": "Amgen Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 49.2489,
"sentiment_score": -0.55575,
"highlights": [
{
"highlight": "<em>Amgen</em> <em>Inc</em>. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.\n\nSector Pharmaceuticals",
"sentiment": -0.7096,
"highlighted_in": "main_text"
},
{
"highlight": "US FDA approves <em>Amgen</em> drug for small cell lung cancer, Bloomberg News reports",
"sentiment": -0.4019,
"highlighted_in": "title"
}
]
},
{
"symbol": "AMGN.BA",
"name": "Amgen Inc.",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "Healthcare",
"match_score": 49.24185,
"sentiment_score": -0.55575,
"highlights": [
{
"highlight": "<em>Amgen</em> <em>Inc</em>. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.\n\nSector Pharmaceuticals",
"sentiment": -0.7096,
"highlighted_in": "main_text"
},
{
"highlight": "US FDA approves <em>Amgen</em> drug for small cell lung cancer, Bloomberg News reports",
"sentiment": -0.4019,
"highlighted_in": "title"
}
]
},
{
"symbol": "AMG.DE",
"name": "Amgen Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 49.238884,
"sentiment_score": -0.55575,
"highlights": [
{
"highlight": "<em>Amgen</em> <em>Inc</em>. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.\n\nSector Pharmaceuticals",
"sentiment": -0.7096,
"highlighted_in": "main_text"
},
{
"highlight": "US FDA approves <em>Amgen</em> drug for small cell lung cancer, Bloomberg News reports",
"sentiment": -0.4019,
"highlighted_in": "title"
}
]
},
{
"symbol": "AMGN.MX",
"name": "Amgen Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 49.233337,
"sentiment_score": -0.55575,
"highlights": [
{
"highlight": "<em>Amgen</em> <em>Inc</em>. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.\n\nSector Pharmaceuticals",
"sentiment": -0.7096,
"highlighted_in": "main_text"
},
{
"highlight": "US FDA approves <em>Amgen</em> drug for small cell lung cancer, Bloomberg News reports",
"sentiment": -0.4019,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "dfbc4965-d04a-477c-b688-577e232fc743",
"title": "Amgen Drug Wins US Approval for Type of Advanced Lung Cancer",
"description": "Amgen Inc. won US approval for a new drug to treat a particularly aggressive form of advanced lung cancer, providing a badly needed new option for patients when chemotherapy stops working.",
"keywords": "Amgen Inc., US approval, lung cancer, chemotherapy, small cell",
"snippet": "Amgen Inc. won US approval for a new drug to treat a particularly aggressive form of advanced lung cancer, providing a badly needed new option for patients when...",
"url": "https://www.livemint.com/news/world/amgen-drug-wins-us-approval-for-type-of-advanced-lung-cancer-11715889383523.html",
"image_url": "https://images.livemint.com/img/2018/12/28/1600x900/News_-_world_1545994908237.jpg",
"language": "en",
"published_at": "2024-05-16T19:56:23.000000Z",
"source": "livemint.com",
"relevance_score": null,
"entities": [
{
"symbol": "AMGN.MX",
"name": "Amgen Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 42.763885,
"sentiment_score": -0.300175,
"highlights": [
{
"highlight": "<em>Amgen</em> <em>Inc</em>. won US approval for a new drug to treat a particularly aggressive form of advanced lung cancer, providing a badly needed new option for patients when chemotherapy stops working.\n\nAmgen’s drug is among the few treatments cleared for patients with small cell lung cancer whose tumors have stopped responding to chemo.",
"sentiment": -0.6557,
"highlighted_in": "main_text"
},
{
"highlight": "The treatment could drive roughly $460 million in sales for <em>Amgen</em> by 2027, according to analysts surveyed by Bloomberg Intelligence.\n\nAmgen’s drug is a bispecific T-cell engager, a type of therapy that harnesses the body’s own immune system to target and fight cancer cells.",
"sentiment": -0.1531,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Amgen</em> also plans to study the drug as an initial treatment for small cell lung cancer.\n\nOther companies are hot on Amgen’s heels in developing new immune therapy drugs for small cell lung cancer. In March, Merck & Co. completed the acquisition of cancer startup Harpoon Therapeutics Inc. for more than $650 million.",
"sentiment": -0.9186,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Amgen</em> Drug Wins US Approval for Type of Advanced Lung Cancer",
"sentiment": 0.5267,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "feeff6d3-bc9d-4143-bd09-f051ad998b9a",
"title": "La FDA américaine approuve le médicament d'Amgen pour le cancer du poumon à petites cellules, selon Bloomberg News",
"description": "La Food and Drug Administration des États-Unis a accordé une autorisation accélérée au tarlatamab, l'immunothérapie ciblée d'Amgen, pour le traitement des adultes atteints d'un cancer du...",
"keywords": "Bourse",
"snippet": "Amgen Inc. figure parmi les 1ers groupes mondiaux de biotechnologie. Le CA par source de revenus se répartit comme suit : - ventes de médicaments (95,5%) : m?...",
"url": "https://www.zonebourse.com/cours/action/AMGEN-INC-4847/actualite/La-FDA-americaine-approuve-le-medicament-d-Amgen-pour-le-cancer-du-poumon-a-petites-cellules-sel-46751575/",
"image_url": "https://www.zonebourse.com/images/twitter_ZB_fdblanc.png",
"language": "fr",
"published_at": "2024-05-16T19:13:55.000000Z",
"source": "zonebourse.com",
"relevance_score": null,
"entities": [
{
"symbol": "AMGN.MX",
"name": "Amgen Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 32.408234,
"sentiment_score": null,
"highlights": [
{
"highlight": "<em>Amgen</em> <em>Inc</em>. figure parmi les 1ers groupes mondiaux de biotechnologie.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "9cbfc048-c5bc-47d0-a08c-99ed95cc3283",
"title": "New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis By Investing.com",
"description": "New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis",
"keywords": "",
"snippet": "Following four years of continuous Sotyktu treatment, clinical response was maintained in more than seven out of 10 patients for Psoriasis Area and Severity Ind...",
"url": "https://www.investing.com/news/press-releases/new-fouryear-sotyktu-deucravacitinib-data-demonstrate-durable-response-rates-and-consistent-safety-in-moderatetosevere-plaque-psoriasis-93CH-3444390",
"image_url": "https://i-invdn-com.investing.com/news/LYNXMPEE6P1NM_L.jpg",
"language": "en",
"published_at": "2024-05-16T14:36:05.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "AMGN.MX",
"name": "Amgen Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 7.003622,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Otezla ® (apremilast) is a registered trademark of <em>Amgen</em> <em>Inc</em> (NASDAQ: ).",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "39bafed8-bab8-4c69-8711-fd3578f603ed",
"title": "Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It",
"description": "Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.",
"keywords": "stock, stocks, investment, investment advice, investing, online trading, online investment, online stock trading, stock market, financial, financial planning, quote, quotes, stock quotes",
"snippet": "This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herei...",
"url": "https://www.zacks.com/stock/news/2274596/amgen-inc-amgn-is-a-trending-stock-facts-to-know-before-betting-on-it?cid=CS-ZC-FT-tale_of_the_tape|most_searched_stocks-2274596",
"image_url": "https://staticx-tuner.zacks.com/images/default_article_images/default191.jpg",
"language": "en",
"published_at": "2024-05-16T13:00:15.000000Z",
"source": "zacks.com",
"relevance_score": null,
"entities": [
{
"symbol": "AMGN.MX",
"name": "Amgen Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 72.78412,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>Amgen</em> <em>Inc</em>. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "AMGN.MX",
"total_documents": 6,
"sentiment_avg": -0.14425500333309174
}
]
}
Other details
Exchange
- Mexican Stock Exchange
- equity
- Healthcare
- mx